Otrivine Sine Conservans Décongestionnant (Xylometazoline Hydrochloride)

Xylometazoline is an alpha‑adrenergic agonist. When applied to the nasal mucosa it stimulates α1‑ and α2‑receptors on the blood vessels, causing vasoconstriction. This reduces swelling of the nasal lining, opens the airway, and improves breathing.

The specific dosing regimen for Otrivine Sine Conservans Décongestionnant is determined by the prescribing healthcare professional. Typically, the prescriber will advise the number of sprays per nostril and the maximum duration of treatment, which should not exceed the recommended limit.

Safety in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Otrivine’s active ingredient, xylometazoline, is an imidazoline‑type decongestant that provides rapid vasoconstriction similar to phenylephrine or oxymetazoline. Compared with some alternatives, xylometazoline may have a slightly longer duration of action, but all topical decongestants share the same risk of rebound congestion if used beyond the recommended period.

Store the nasal spray at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Otrivine is administered as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks include severe hypertension, tachycardia, arrhythmias, nasal ulceration, and rebound congestion (rhinitis medicamentosa) after prolonged use. Patients experiencing any of these symptoms should discontinue use and seek medical attention promptly.

Individuals with known hypersensitivity to xylometazoline or any other component of the formulation should avoid use. Patients with uncontrolled hypertension, severe cardiovascular disease, or those already using other nasal decongestants should consult a healthcare professional before using Otrivine.